Table 3.

Differential risk stratification of patients with discordant scores based on Clinical Oncotype Dx and NanoString Oncotype Dx recurrence scores

Number of PatientsRisk from Clinical Oncotype Dx recurrence scores (clinRS)Risk from NanoString Oncotype Dx recurrence scores (nstringRS)
7/71 (9.9%)LowIntermediate
4/71 (5.6%)IntermediateHigh
5/71 (7.0%)IntermediateLow
1/71 (1.4%)HighIntermediate